American Journal on Addictions’ (AJA) editor, Thomas R. Kosten, has been ranked by ScholarGPS 10th worldwide in the field of addictions and in the top .03% worldwide across all specialties.
AJA is the medical journal of the American Academy of Addiction Psychiatry (AAAP). AAAP applauds Dr. Kosten’s dedication for research in the field of Addiction Psychiatry and congratulates him on this achievement!
The ScholarGPS platform uses artificial intelligence and data technologies to rank academic institutions and programs based on faculty members’ quality and quantity of research output. Institutional rankings take into account the active scholars in each institution who are highly productive in terms of their number of publications and have generated outstanding work of meaningful impact, indicated by citations.
Dr. Kosten’s work has been published 864 times, with predicted citations at 44,830, and has achieved the status of Highly Ranked Scholars–Lifetime by Scholar GPS. He is the JH Waggoner Chair and Professor of Psychiatry, Pharmacology, Immunology, Pathology and Neuroscience, vice-Chair for Psychiatry and Emeritus Director of the Dan Duncan Institute for Clinical and Translational Research at Baylor College of Medicine.
His other key appointments are Distinguished Professor of Psychiatry at Peking University Medical School and Professor of Epidemiology and Behavioral Health at MD Anderson Cancer Center. He is a former Professor at Yale University School of Medicine, the founding Vice Chair for Addiction Psychiatry of the American Board of Psychiatry and Neurology, and Past President of both the American Academy of Addiction Psychiatry and the College on Problems of Drug Dependence. He is a Distinguished Life Fellow in the American Psychiatric Association and a Fellow of the American College of Neuropsychopharmacology. He has served as a Congressional Fellow in the US House of Representatives and is a long-standing member of various commissions with the National Academy of Sciences, the Food and Drug Administration, the Federal Trade Commission, and the Department of Defense primarily related to veteran health and drug safety and risk management.
